Actively Recruiting
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Led by Sun Yat-sen University · Updated on 2026-04-21
36
Participants Needed
1
Research Sites
565 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer.
CONDITIONS
Official Title
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with unresectable stage III non-small cell lung cancer
- Provided written informed consent
- No previously detected sensitizing EGFR mutation or ALK fusion oncogene
- Male or female aged 18 years or older and younger than 75 years
- Able to follow the study protocol and attend follow-up visits
- Able to take oral medications
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 12 weeks
- Adequate blood cell counts: ANC ≥ 2.0 x 10^9/L, Platelets ≥ 100 x 10^9/L, Hemoglobin ≥ 9 g/dL (transfusion allowed to maintain level)
- Adequate liver function: Total bilirubin ≤ 1.5 times upper limit of normal (ULN); AST and ALT ≤ 2.5 times ULN without liver metastases or ≤ 5 times ULN with liver metastases
- Adequate kidney function: Serum creatinine ≤ 1.25 times ULN or creatinine clearance ≥ 60 ml/min
- Female participants must not be pregnant or breastfeeding
You will not qualify if you...
- Known severe allergy to IBI308 or its ingredients
- Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies
- Previous chemotherapy or radiotherapy
- Active, known, or suspected autoimmune disease requiring systemic treatment
- Use of systemic corticosteroids (>10 mg prednisone daily) or immunosuppressive drugs within 14 days before study treatment
- Unable to comply with study procedures
- Serious systemic disorders that could affect study completion
- Serious heart conditions such as recent heart attack (within 6 months), angina, or heart disease
- History of another cancer within 5 years except for certain cured skin or cervical cancers
- Unstable systemic diseases including infections, uncontrolled blood pressure, or heart failure
- Active serious infection with fever ≥ 38.0°C
- Known HIV infection or AIDS
- Known active Hepatitis B or C infection
- Pregnant or nursing women
- Any other disease or condition that could increase risk or interfere with treatment safety or effectiveness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
S
Si-Yu Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here